Market
Concentrated second-half shipments of improved Euvichol-S to offset uneven results

EuBiologics has signed a contract with UNICEF to supply oral cholera vaccines worth 10.46081 billion won.
EuBiologics said in a disclosure on the 26th that it had signed a contract to supply UNICEF with Euvichol-S for Mozambique. The contract runs for about 100 days, from Oct. 23, 2026, to Jan. 31, 2027.
The contract is seen as a turning point in offsetting quarterly earnings fluctuations that persisted throughout the first half with concentrated shipments in the second half, rather than for the size of the order alone. Short-term earnings volatility has increased as the timing of purchase order receipts varies under international organizations’ procurement structures.
EuBiologics recorded annual revenue of 149.2 billion won and operating profit of 60.7 billion won on a separate basis in 2025, with an operating margin above 40%. However, more than 97% of total revenue came from a single product, oral cholera vaccine, causing quarterly results to fluctuate significantly depending on order timing and shipping schedules.
Revenue fell sharply to 15.6 billion won and operating profit to about 2.2 billion won in the first quarter of 2026. The decline resulted from delayed order schedules and a high-base effect following strong results the previous year. Cumulative first-half revenue also reached only 48.9 billion won.
This contract follows orders signed in the second quarter for Angola (8.5 billion won) and Nigeria (13.3 billion won), as well as a contract worth 10.1 billion won disclosed July 14. Under a structure in which annual consolidated procurement requests from international organizations are divided into local purchase orders by quarter, revenue recognition has continued across the third and fourth quarters.
The product covered by this contract is the improved vaccine Euvichol-S, rather than the original Euvichol or Euvichol-Plus. Euvichol-S is a third-generation product whose improved bulk manufacturing process has increased antigen production yield by about 40% compared with the previous product.
EuBiologics secured World Health Organization prequalification (WHO-PQ) approval for the bulk and finished-product facilities at its second plant in Chuncheon, increasing annual production capacity from 33 million doses to as many as 90 million doses. As the higher-yield product enters full-scale shipment, lower manufacturing costs per batch are expected to strengthen the company’s ability to protect its operating margin.
Supply-demand imbalances in the global cholera vaccine market are also supporting the pace of shipments. The emergency stockpile benchmark recommended by UNICEF and the International Coordinating Group on Vaccine Provision (ICG) is about 5 million doses, but actual stockpiles have fallen below the recommended level amid recent outbreaks in Africa and the Middle East and the resumption of vaccination campaigns.
EuBiologics is effectively the only manufacturer exclusively supplying oral cholera vaccines to the global public procurement market. As the only supplier with a production system capable of making 90 million doses, it can maintain stable margins without price-cutting pressure in a supplier-favorable environment.
However, the company’s heavy reliance on a single cholera vaccine product and a single customer, UNICEF, remains a risk. Quarterly results could change sharply depending on international organizations’ financial conditions, order execution schedules and exchange-rate fluctuations.
The disclosed contract value of 10.46081 billion won was calculated using the exchange rate on the contract date (1,326 won per dollar). The final amount received could also vary with exchange-rate movements.
EuBiologics’ medium- to long-term earnings stability depends on how quickly it can commercialize follow-on products using cash flow generated by Euvichol-S. The company is pursuing diversification of its public vaccine portfolio, preparing a typhoid conjugate vaccine (EuTYPH-C), which has received product approval from the Ministry of Food and Drug Safety and is under WHO-PQ review, as well as a pentavalent meningococcal vaccine in clinical development.

Biobook Team
biobookmedia@biobook.co.kr
Charles River Acquires Two Frontage Bioanalytical Laboratories for $470 Million

Sanofi-Backed Windward Raises $225 Million in IPO to Develop Respiratory Drugs From China

PharmaResearch Reports Third-Quarter Operating Profit of KRW 186.4 Billion, Up 14.7% Year Over Year

Hanmi Pharmaceutical’s Operating Profit Reaches ₩222.6 Billion in First Three Quarters, Up 27.5% Year Over Year

Kolon TissueGene Posts 73.3 Billion Won in Net Income Through Q3, Returns to Profit

BlueMtec Posts 5.5 Billion Won in Net Income Through Q3, Returning to Profit From a Year-Earlier Loss